Outsourced Business Development for Life Sciences: How It Works and When It Pays Off
Updated: 20 hours ago
Updated 26 October 2026. First published in July 2025.
Outsourced business development is when a life sciences service company hands prospecting, outreach, meeting generation and pipeline management to a specialist external team instead of hiring in-house. It works when the partner knows the sector, targets a narrow ICP and reports on outcomes, not activity.
In life sciences, building a consistent pipeline of qualified opportunities is one of the most important and most difficult parts of growth. Most CROs, CDMOs and specialist service providers are built around scientific and operational excellence, not around a sales function. This guide explains what outsourced business development services include, how they compare with an in-house hire, how they are priced, and how to tell a good partner from a bad one.
Looking for an outsourced BD partner for your CRO or CDMO? See Corstrate's outsourced business development services.
Key Takeaways
Outsourced business development gives a small life sciences company a working commercial function without a hiring cycle.
It covers targeting, outreach, meeting generation, pipeline management and reporting, usually by email, LinkedIn and conferences.
A senior in-house BD director in the US typically costs more than USD 118,000 in base salary alone, before variable pay and benefits.
Fixed retainers favour fit and consistency; pay-per-meeting models can favour volume over quality.
It fails when the partner is generic. Sector knowledge, a narrow ICP and transparent reporting are what make it work.
Why life sciences companies outsource business development
Most life sciences service companies are not structured to run business development internally. The core team is made up of scientists, engineers, quality and operations experts, not full-time sales professionals. Business development ends up with the founder or a senior scientist, squeezed between delivery and management.
Outsourcing lets the company keep its people on delivery and innovation, while experienced business development consultants handle targeting, outreach, relationship building and opportunity sourcing. In 2026 there is an extra reason to get this right: HSBC Innovation Banking reports that the top 10% of first financings took 63% of the money raised by biotechs in H1 2026, so the well-funded sponsors are fewer and competition for their attention is higher.
What outsourced business development services include
A complete outsourced BD engagement for a CRO, CDMO or service provider usually covers six building blocks:
ICP and targeting: defining which sponsors to pursue by modality, phase, therapeutic area, size and geography, then building the account list.
Buying signals: tracking financings, new trials, pipeline moves, leadership changes and acquisitions that indicate an account is ready to talk.
Outreach: personalised, scientifically credible messages by email and LinkedIn, sequenced over several weeks.
Meeting generation: booking qualified meetings before industry events such as BIO, DCAT, CPHI and BIO-Europe, see our conference meeting generation service.
Pipeline management: logging every conversation in the client's CRM so the pipeline belongs to the client, not to the agency.
Reporting and market feedback: monthly reporting on meetings, opportunities and objections heard in the market.
Some companies only need the top of this list, which is closer to life science lead generation. Others need the whole function run for them on an ongoing basis, which is fractional business development.
Outsourced vs in-house business development
The real comparison is not price per month, it is cost and time to a productive pipeline. PayScale puts the average US base salary of a business development director at about USD 117,900 in 2026, with the 90th percentile near USD 178,000 and bonuses and commissions on top. A CRO's own job posting from June 2026, for a Director of Business Development, US East, listed a base of USD 130,000 to 155,000. Add benefits, travel, data tools, recruiting time and a ramp-up period of several months before the new hire produces pipeline.
Time to start: an in-house hire takes months to recruit and onboard. An outsourced team starts outreach within weeks.
Cost structure: an in-house hire is a fixed annual commitment. Outsourcing is a contract that can be scaled or stopped.
Expertise: a single hire brings one person's network. A specialist partner brings a method, data and experience across many campaigns.
Control: in-house gives full control. A good partner compensates with shared CRM, weekly visibility and monthly reporting.
Long term: many companies outsource first, prove the market and the message, then hire in-house with a working playbook.
Engagement and pricing models
Outsourced business development is sold in three main ways, and the model shapes the behaviour you get:
Monthly retainer: a fixed fee for an agreed scope and effort. It rewards fit, consistency and strategy, and suits long sales cycles.
Project fee: a defined campaign, such as a market entry test, a US launch or a conference meeting campaign.
Pay-per-meeting or commission: payment per meeting booked or per deal closed. It looks low-risk, but it can push volume over fit, and commission on multi-year service contracts becomes expensive.
Corstrate works on a fixed monthly fee, paid at the start of each month, because life sciences sales cycles are long and the work that produces a signed contract starts months before the signature.
Why life sciences needs a specialist partner
Generic sales tactics do not work with scientific buyers. What you need from a partner is:
Scientific messaging that resonates with clinical, CMC, quality and procurement decision-makers
Knowledge of regulatory context and sponsor procurement processes
Understanding of how biotech and pharma buyers shortlist and qualify vendors
The right outsourced BD team brings sector-specific knowledge and reaches your ideal clients with credibility and precision. The wrong one sends volume and damages your reputation with the very sponsors you want to win.
How fast does it work?
Because there is no hiring or onboarding cycle, outreach can start within weeks and the first qualified meetings usually follow soon after. Signed contracts take longer: sponsor decisions in life sciences are committee-driven and often take several months, which is why consistent pipeline management matters as much as the first meeting.
When outsourced business development fails, and how to choose a partner
Outsourcing fails when it is done without industry alignment, strategy or transparency. Before signing, ask any potential partner:
Who exactly will write to my prospects, and what is their life sciences experience?
How will you define and validate our ICP before outreach starts?
Which channels will you use, and what will a message to a sponsor look like?
Will the pipeline live in our CRM, and what do we own if we stop?
What will you report every month: activity, or meetings, opportunities and market feedback?
What is the minimum commitment, and how is the fee structured?
A credible partner answers all six clearly, before the contract, not after.
US and UK: what changes
For UK and European service providers selling into the US, outsourcing also solves a presence problem: time-zone coverage, US conference meetings and a network that a European team does not yet have. For US companies selling into the UK and Europe, the reverse applies, with BIO-Europe and CPHI as the main meeting points. Our article on H2 2026 BD priorities lists the events left before the 2027 budget cycle.
Final thoughts
Outsourcing business development is not a shortcut, it is a strategic choice. If your internal team is at capacity, or you want to enter a new market without the risk of an early senior hire, an outsourced or fractional business development model can be the fastest route to a predictable pipeline, provided the partner knows your sector.
Corstrate is a PharmD-led business development consultancy for CROs, CDMOs and life sciences service providers selling to pharma and biotech in the US, UK and Europe. Book a call to see what outsourced business development could look like for your company.
Frequently asked questions
What is outsourced business development in life sciences?
Outsourced business development is when a CRO, CDMO or other life sciences service company hands prospecting, outreach, meeting generation and pipeline management to a specialist external team instead of building that function in-house.
What do outsourced business development services include?
Typically: ICP definition and account targeting, buying-signal research, outreach by email and LinkedIn, meeting generation around conferences, pipeline management in the client's CRM, and monthly reporting on meetings, opportunities and market feedback.
Is outsourced business development cheaper than hiring in-house?
Usually, for small companies. PayScale puts the average US base salary of a business development director at about USD 118,000 in 2026, before bonus, commission, benefits, tools and recruiting time. An outsourced team starts without a hiring cycle and can be scaled up or down by contract.
How long does outsourced business development take to produce results?
First qualified meetings usually come within the first weeks of outreach, because there is no hiring or onboarding cycle. Signed contracts take longer, because sponsor decisions in life sciences often take several months.
How should outsourced business development be priced?
The common models are a fixed monthly retainer, a project fee for a defined campaign, and pay-per-meeting or commission. Retainers buy consistent effort and strategy, while pay-per-meeting models can push volume over fit. Corstrate works on a fixed monthly fee, paid at the start of each month.
When does outsourced business development fail?
When the partner does not understand the sector, targets too broadly, sends generic messages, or reports activity instead of outcomes. Success depends on a narrow ICP, scientifically credible messaging and transparent reporting.
Comments